CCHFVACIM reaches key milestones in its first reporting period.
The CCHFVACIM project has made significant progress during its first reporting period (January 2024 – June 2025), laying strong foundations for the development of innovative vaccines and immunotherapies against Crimean-Congo Haemorrhagic Fever (CCHF).
Among the key achievements, the consortium successfully designed and evaluated multiple mRNA-based vaccine candidates. Early in vivo studies have shown promising results, with the lead candidate inducing both B-cell and T-cell responses, as well as the production of neutralizing antibodies.
In parallel, the project has advanced the development of critical research tools, including validated neutralization assays and new animal models, which will support future preclinical testing. A high-quality biobank of patient samples has also been established, enabling deeper investigation of immune responses and accelerating therapeutic antibody development.
These results mark an important step forward in strengthening Europe’s preparedness against high-consequence viral threats and demonstrate the strong momentum of the CCHFVACIM consortium.
